Drug treatment possible for reversing autism
Researchers have found a critical and previously unknown link between synthesis of brain proteins and autism spectrum disorders that they say could lead to new treatments. In their studies, scientists were able to reverse ASD behaviors in mice by manipulating brain cell signals, which could lead to the development of drugs to reverse ASD associated behaviors.
McGill University scientists explain mouse studies show symptoms that develop and associated with ASD are the result of abnormally high synthesis of a group of proteins called neuroligins.
Neuroligins are molecules that are involved in sending brain signals. The molecules bind with a ligand (another group of molecules or ions) to transmit and process information in the brain.
Prof. Nahum Sonenberg, from McGill’s Dept. of Biochemistry, Faculty of Medicine, and the Goodman Cancer Research Centre explained in a press release: “We used a mouse model in which a key gene controlling initiation of protein synthesis was deleted.
In these mice, production of neuroligins was increased. Neuroligins are important for the formation and regulation of connections known as synapses between neuronal cells in the brain and essential for the maintenance of the balance in the transmission of information from neuron to neuron.”
When the researchers blocked synthesis of the proteins with gene therapy they were able to reverse autism like behaviors.
Christos Gkogkas, a postdoctoral fellow at McGill and lead author. “Our work is the first to link translational control of neuroligins with altered synaptic function and autism-like behaviors in mice.
Neuroligin mutation was first discovered in 2003 and linked to autism spectrum disorders, but research hasn’t uncovered the exact mechanism of how the mutations lead to ASD symptoms.